Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhysiomics Regulatory News (PYC)

Share Price Information for Physiomics (PYC)

Share Price is delayed by 15 minutes
Get Live Data
0.60    0.00 (0.00%)
Bid:
0.55
Ask:
0.65
Spread: 0.10 (18.182%)
Market Cap: £2.72m
PYC Live PriceLast checked at - London Stock Exchange

Intraday Physiomics Share Chart

Conversion of Loan Note

18 Dec 2009 13:06

RNS Number : 3955E
Physiomics PLC
18 December 2009
 



Physiomics plc

(the "Company")

Conversion of Loan Note

The Company announces that pursuant to the terms of a loan note dated 8 February 2008 and made between (i) Energiser Investments plc and (ii) the Company, (the "Loan Note"), Energiser Investments plc has requested that the full amount drawn down under the Loan Note be converted into ordinary shares in the Company.

Under the Loan Note, which was announced to the market on 15 February 2008, Energiser Investments plc (formerly Billam plc) advanced £50,000 to the Company, which is convertible into ordinary shares at a price of 0.1p per share.

The total number of shares to be issued to Energiser Investments plc, pursuant to the terms of the loan note, is therefore 50,000,000 Ordinary Shares (the "Conversion Shares")

Application has been made to admit the Conversion Shares to trading on AIM, and dealings in the Conversion Shares is expected to commence on 24 December 2009. Following the issue of the Conversion Shares, the total issued share capital of the Company will be 998,570,699 Ordinary Shares.

On 9 December 2009 it was announced that Energiser Investments plc then held 100,004 ordinary shares in the Company. Following the issue of the Conversion Shares and taking into account the holding notified on 9 December 2009, Energiser Investments plc will hold 50,100,004 Ordinary Shares in the Company, representing 5.017% of the then issued share capital. 

Enquiries:

Physiomics plc

Dr Christophe Chassagnole, COO 

+44 (0)1865 784980

WH Ireland Limited

Katy Mitchell

+44 (0161 832 2174

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGGMMZFRDGLZM
Date   Source Headline
19th Jan 201810:20 amRNSHolding(s) in Company
17th Jan 20183:52 pmRNSHolding(s) in Company
13th Dec 20172:06 pmRNSResult of AGM
12th Dec 201710:17 amRNSDirector Dealing
6th Dec 20173:00 pmRNSIssue of Equity
30th Nov 20171:38 pmRNSShare Price Movement
28th Nov 20177:00 amRNSClinical Project Completion and Services Agreement
9th Nov 20177:00 amRNSDispatch of Annual Report and Shareholder Circular
16th Oct 20177:00 amRNSFinal Results
2nd Oct 20177:00 amRNSCompany Update
31st Jul 20177:00 amRNSTwo New Pre-Clinical Contracts
6th Jun 20177:00 amRNSPhysiomics to Attend PAGE 2017
24th May 20177:00 amRNSUpdate: Two Further Extension Projects
5th May 20177:00 amRNSPhysiomics to Present at BioTrinity 2017
24th Mar 201711:15 amRNSInterim Results Statement
11th Jan 20177:00 amRNSCompany Update
6th Jan 20177:00 amRNSConfirmation of Award of Innovate UK Grant
22nd Dec 20163:31 pmRNSDirector Dealing
22nd Dec 20167:00 amRNSIssue of Options
16th Dec 20161:00 pmRNSResult of AGM
5th Dec 20167:00 amRNSPayment for in-silico modelling of inhibitor
23rd Nov 20167:00 amRNSPosting of Financial Results and Notice of AGM
22nd Nov 20167:00 amRNSProvisional Award of Innovate UK Grant
27th Oct 20163:00 pmRNSFinal Results for the year ended 30 June 2016
26th Oct 20167:00 amRNSPresentation at Conference on Pharmacometrics
25th Oct 20167:00 amRNSDirectorate Change
28th Sep 20167:00 amRNSAdvisor Changes
21st Sep 20167:00 amRNSPlacing and Update on Acquisition
7th Sep 201612:19 pmRNSResult of GM
22nd Aug 20167:00 amRNSNotice of General Meeting
18th Aug 20167:00 amRNSSigning of Share Purchase Agreement with BioMoti
16th Aug 20161:05 pmRNSAdvisor Changes
16th May 20167:00 amRNSExtensions for Virtual Tumour Project
3rd May 20167:00 amRNSAppointment of part-time Head of Finance
18th Apr 20169:02 amRNSPhysiomics Appoints New Chief Executive Officer
6th Apr 201610:15 amRNSVirtual Tumour Developments Presentation at AACR
4th Apr 201612:12 pmRNSNew Speciality Pharma Customer for new Indication
31st Mar 20167:01 amRNSInterim Results Statement
31st Mar 20167:00 amRNSHeads of Terms with BioMoti and Board Changes
22nd Dec 201512:08 pmRNSIssue of Options
22nd Dec 20157:00 amRNSNew Speciality Pharma Customer for New Indication
18th Dec 201510:57 amRNSPlacing
14th Dec 201510:29 amRNSResult of General Meeting
4th Dec 201511:38 amRNSResult of AGM
27th Nov 20154:15 pmRNSNotice of General Meeting
10th Nov 20157:00 amRNSFinal Results
6th Nov 20157:00 amRNSStrategic Update
12th Oct 20157:00 amRNS4th Large Pharma Customer for Virtual Tumour
9th Oct 20157:00 amRNSProject extension with global pharma company
4th Aug 20157:01 amRNSProf. Mark Middleton appointed to Physiomics SAB

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.